NICE recommends Forxiga (BMS/AstraZeneca) for treatment of Type 2 Diabetes

The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination recommending the use of Forxiga (dapagliflozin), the first in class SGLT 2 inhibitor from BMS and AstraZeneca. NICE recommends Forxiga as a treatment option for adults with Type 2 Diabetes as dual therapy in combination with metformin, and in combination with insulin with or without other oral anti-diabetic drugs. The Institute recommends Forxiga to be used in combination with metformin instead of a sulphonylurea in certain patients for whom an sulphonylurea is not tolerated/contraindicated or who are at significant risk of hypoglycaemia or its consequences. The addition of Forxiga to metformin may be preferable to a thiazolidinedione if further weigh gain is a concern.